A股異動丨瑞豐光電逼近漲停 Mini背光產品開始向多家客户小批量出貨
格隆匯12月16日丨瑞豐光電(300241.SZ)逼近漲停,報7.49元,總市值40億元。

瑞豐光電上週在全景網投資者關係互動平台介紹,公司Mini相關技術可應用到手機、電視、平板、VR等各類電子產品,與國內外知名電子企業緊密合作開發了各類Mini背光和顯示產品方案,建成了國內第一條MiniLED自動化生產線。公司稱,截至目前,Mini背光產品已經開始向多家客户小批量出貨,公司計劃對生產線進一步擴充。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.